ACTEMRA

This brand name is authorized in Australia, Brazil, Canada, Ecuador, Hong Kong, Japan, New Zealand, Singapore, Tunisia, Turkey, United States, South Africa

Active ingredients

The drug ACTEMRA contains one active pharmaceutical ingredient (API):

UNII I031V2H011 - TOCILIZUMAB

Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R). IL-6 is involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, induction of hepatic acute phase protein synthesis and stimulation of haemopoiesis. IL-6 has been implicated in the pathogenesis of diseases including inflammatory diseases, osteoporosis and neoplasia.

Read about Tocilizumab

Medication package inserts

Below package inserts are available for further reading:

Title
Information Source
Document Type
 
FDA, National Drug Code (US)
MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
Tocilizumab
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
AU
Pharmaceutical Benefits Scheme
Identifier(s): 10056G, 10058J, 10060L, 10064Q, 10068X, 10071C, 10072D, 10073E, 10077J, 10078K, 10079L, 10081N, 10951J, 10954M, 11565Q, 11567T, 11720W, 11721X, 11722Y, 11725D, 11730J, 11734N, 11741Y, 11742B, 11743C, 11744D, 11748H, 11750K, 12083Y, 12084B, 12085C, 12086D, 12090H, 12094M, 12095N, 12099T, 12102Y, 12105D, 1419Q, 1423X, 1464C, 1476Q, 1481Y, 1482B, 9657G, 9658H, 9659J, 9671B, 9672C, 9673D
BR
Câmara de Regulação do Mercado de Medicamentos
Identifier(s): 529208501150212, 529208502157210, 529215110026303, 529220090026707, 529220090026807
CA
Health Products and Food Branch
Identifier(s): 02350092, 02350106, 02350114, 02424770, 02483327
EC
Agencia Nacional de Regulación, Control y Vigilancia Sanitaria
Identifier(s): 202-MBE-0621, 28938-07-09
HK
Department of Health Drug Office
Identifier(s): 59200, 59201, 59202, 63771
JP
医薬品医療機器総合機構
Identifier(s): 6399421A1020, 6399421A2026, 6399421A3022, 6399421G1022, 6399421G2029
NZ
Medicines and Medical Devices Safety Authority
Identifier(s): 13435, 15812
SG
Health Sciences Authority
Identifier(s): 13723P, 14837P
TN
Direction de la Pharmacie et du Médicament
Identifier(s): 6993201H, 6993202H, 6993203H, 6993204H
TR
İlaç ve Tıbbi Cihaz Kurumu
Identifier(s): 8699505762272, 8699505762289, 8699505762296, 8699505762302, 8699505762319, 8699505762326, 8699505952840
US
FDA, National Drug Code
Identifier(s): 50242-135, 50242-136, 50242-137, 50242-138, 50242-143
ZA
Health Products Regulatory Authority
Identifier(s): 43/30.1/0944, 43/30.1/0945, 43/30.1/0946, 49/30.1/0398

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.